Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Related Posts
Yan MJ, Poppens MJ, Longstaff XR, Collier EK, Davis JC. Evaluating the Role of Dermatologic Continuity and Determinants of Psychiatric Engagement in Delusional Infestation: A[...]
Varghese MS, Han L, Gandhi PU, Skanderson M, Wu WC, Drwal KR, Burg MM, Kazi DS, Gaffey AE, Levy DR, Feder S, Bean Mayberry BA,[...]
Blofield M, Danforth K, Matthews S, Acuña D, Armocida B, Bevilacqua PD, Delany A, Bhate-Deosthali P, Formenti B, González MA, Madera N, Malta D, Mugerwa[...]